Pancreas Cancer Clinical Trials
2 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 1Phase 2
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Breast CancerLung CancersOvarian Cancer+4 more
Filamon LTD80 enrolled3 locationsNCT06926075
Recruiting
Phase 2
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Lung CancerPancreas CancerRadiation Fibrosis+1 more
Massachusetts General Hospital72 enrolled1 locationNCT04485286
Recruiting
Phase 1Phase 2
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Lung CancerPancreas CancerThyroid Cancer+1 more
Sichuan Enray Pharmaceutical Sciences Company54 enrolled9 locationsNCT07433283
Recruiting
Phase 1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
MOMA Therapeutics220 enrolled18 locationsNCT06545942
Recruiting
Not Applicable
Stereotactic Magnetic Resonance Guided Radiation Therapy
Prostate CancerLung CancerSpine Metastases+10 more
Dana-Farber Cancer Institute397 enrolled2 locationsNCT04115254
Recruiting
Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Pancreas CancerPeutz-Jeghers Syndrome (PJS)Gene Mutation+2 more
Johns Hopkins University9,000 enrolled9 locationsNCT02000089
Recruiting
Phase 1
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Esophageal CancerGastric CancerLung Cancer+3 more
Chongqing Precision Biotech Co., Ltd108 enrolled1 locationNCT07179692
Recruiting
Phase 1Phase 2
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Gastric CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+3 more
Shanghai Public Health Clinical Center40 enrolled1 locationNCT03093688
Recruiting
Phase 1
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Breast CancerOvarian CancerProstate Cancer+6 more
Nammi Therapeutics Inc100 enrolled8 locationsNCT06582017
Recruiting
Phase 1Phase 2
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+4 more
Chongqing Precision Biotech Co., Ltd60 enrolled3 locationsNCT06006390
Recruiting
Phase 2Phase 3
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Breast CancerOvarian CancerCervical Cancer+7 more
Second Affiliated Hospital of Guangzhou Medical University200 enrolled1 locationNCT03755739
Recruiting
Phase 2
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Lung CancerMelanomaPancreas Cancer+4 more
N.N. Petrov National Medical Research Center of Oncology20 enrolled1 locationNCT06229340
Recruiting
Phase 1
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
Breast CancerGastric CancerCholangiocarcinoma+5 more
Chongqing Precision Biotech Co., Ltd60 enrolled1 locationNCT06126406
Recruiting
Phase 1
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
Breast CancerGastric CancerCholangiocarcinoma+4 more
Chongqing Precision Biotech Co., Ltd36 enrolled1 locationNCT06010862